Rhythm Pharmaceuticals, Inc.
RYTMHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeRhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company carries a $7.31B market cap, placing it firmly in the mid-cap category. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity.
Market Cap
$7.31B
Beta
1.88
P/E (TTM)
—
P/E (Fwd)
-145.55
EPS (TTM)
$-3.14
EPS (Fwd)
$-0.73
ROE
-101.2%
ROA
-29.8%
Cash
$340.6M
Total Debt
$112.3M
Free CF
-$150.7M
52W Change
19.5%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $340.6M in cash comfortably exceeding the $112.3M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$150.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -101.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $23.6M (2022) to $189.8M (2025), reflecting a 703% increase over the period.
A beta of 1.88 means RYTM is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Rhythm Pharmaceuticals, Inc. and its sector.